Monday, October 26, 2026

Market Impact

3 articles

Central Banks Hold Rates as Fed, ECB, Brazil Signal Extended Pause Through 2026

Central Banks Hold Rates as Fed, ECB, Brazil Signal Extended Pause Through 2026

The Federal Reserve, European Central Bank, Bank of Russia, and Brazil's central bank are maintaining current interest rates in March 2026, marking a shift from earlier easing expectations. Former Cleveland Fed President Loretta Mester says the Fed needs restrictive policy until inflation convincingly reaches 2%. Brazil's monetary policy director warns new geopolitical risks, including the Iran conflict, complicate the outlook for rate cuts.

ViaNews Editorial Team (Markets)•
AI Disruption Sends Mixed Signals: Wealth Management Stocks Slide as Enterprise Adoption Surges

AI Disruption Sends Mixed Signals: Wealth Management Stocks Slide as Enterprise Adoption Surges

Markets are recalibrating around AI's uneven economic impact as wealth management stocks sell off on disruption fears while enterprise platforms scale at record pace. Guidance misses from S&P Global and On Semiconductor contrast sharply with Microsoft's capacity-constrained Azure AI infrastructure and Meta's $115-135 billion capex commitment. Investors face a bifurcated landscape where AI's transformative promise collides with near-term earnings pressure across sectors.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com